Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 16, 2024

Preoperative Durvalumab or Durvalumab Plus Tremelimumab for Resectable HNSCC

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
Clin. Cancer Res 2024 Mar 08;[EPub Ahead of Print], CG Kim, MH Hong, D Kim, BH Lee, H Kim, CY Ock, G Kelly, YJ Bang, G Kim, JE Lee, C Kim, SH Kim, HJ Hong, YM Park, NS Sim, H Park, JW Park, CG Lee, KH Kim, G Park, I Jung, D Han, JH Kim, J Cha, I Lee, M Kang, H Song, C Oum, S Kim, S Kim, Y Lim, S Kim-Schulze, M Merad, SO Yoon, HJ Kim, YW Koh, HR Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading